Allergy & Immunology

Filter

Rilzabrutinib Offers Hope for Patients with Refractory Urticaria

April 2025

The RILECSU phase 2 clinical trial has introduced a potential new option: rilzabrutinib.

Introducing EMJ Nephrology 4.1

United Kingdom, July 5, 2016: Welcome to the 2016 edition of EMJ Nephrology, which provides extensive coverage of research and developments across the…

EMJ

T Cell Protein Provides New Leads in Understanding Immune Response

AN INNOVATIVE new study has uncovered a protein that is fundamental to controlling immune responses, which could provide much needed clarification of…

EMJ

New Insight into the Components of Pollen Proves Positive for Hay Fever Sufferers

NON-ALLERGENIC components of pollen do impact the body’s immune system, a recent study has uniquely revealed. The discovery could transform the future…

EMJ

Patient Enrolment Completed in US Phase IIb Study of GrassMATAMPL

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces it has completed…

EMJ

Introducing the European Medical Journal 1.1

United Kingdom, February 19, 2016: The first edition of the European Medical Journal is available now, this is the first of four issues new for 2016.

EMJ

Optimised Antibiotic Regimens May Reduce TB Treatment Failures

NOTORIOUSLY difficult to treat, antibiotic-resistant tuberculosis (TB) would develop less frequently if there was greater optimisation of…

EMJ

How Giant Cells Dispose of Giant Waste

PHAGOCYTIC multinucleated giant cells (MGCs) act as the waste disposal men of the body by clearing away bulky waste materials that carry the potential…

EMJ

How the Body Stops the Type 2 Immune Response and Onset of Allergic Disease

SUPPRESSION of group 2 innate lymphoid (IL2) cells following infection has been shown to prevent the innate immune response from continuing when…

Loading posts...

« Previous 1 … 24 25 26 27 Next »